Pyridostigmin Orifarm
Acetylcholinesterase Inhibitor for Myasthenia Gravis
Quick Facts About Pyridostigmin Orifarm
Key Takeaways
- Pyridostigmine bromide is the first-line symptomatic treatment for myasthenia gravis, improving muscle strength by enhancing neuromuscular transmission.
- The medication acts within 30–45 minutes and lasts 3–6 hours, requiring multiple daily doses for continuous symptom control.
- Common side effects are cholinergic in nature (gastrointestinal symptoms, increased secretions) and are usually dose-related and manageable.
- Pyridostigmine must not be used in patients with mechanical bowel obstruction or urinary tract obstruction.
- Careful dose titration by your physician is essential — both underdosing and overdosing can cause muscle weakness, and distinguishing between the two is clinically critical.
What Is Pyridostigmin Orifarm and What Is It Used For?
Pyridostigmin Orifarm belongs to a class of medications known as acetylcholinesterase inhibitors (also called anticholinesterase agents or parasympathomimetics). The active substance, pyridostigmine bromide, inhibits the enzyme acetylcholinesterase, which is responsible for breaking down the neurotransmitter acetylcholine at nerve-muscle junctions. By slowing this breakdown, more acetylcholine remains available to stimulate muscle contraction, resulting in improved muscle strength and function.
The primary indication for Pyridostigmin Orifarm is myasthenia gravis, a chronic autoimmune neuromuscular disorder. In myasthenia gravis, the body's immune system produces antibodies that attack and destroy acetylcholine receptors at the neuromuscular junction. This leads to the hallmark symptoms of the disease: fluctuating skeletal muscle weakness that worsens with activity and improves with rest. Pyridostigmine does not address the underlying autoimmune process, but provides symptomatic relief by increasing the amount of acetylcholine available to bind to the remaining receptors.
Myasthenia gravis affects approximately 15–25 per 100,000 people worldwide, according to epidemiological data reviewed by the American Academy of Neurology (AAN) and the European Academy of Neurology (EAN). The condition can affect people of any age but has a bimodal peak — younger women (20–40 years) and older men (60–80 years) are most commonly affected. Symptoms typically begin with ocular weakness (drooping eyelids, double vision) and may progress to generalised weakness affecting limb muscles, bulbar muscles (swallowing, speech), and respiratory muscles.
Pyridostigmin Orifarm is also used for the treatment of intestinal atony (reduced or absent motility of the intestines). In this condition, the smooth muscle of the intestinal wall fails to contract adequately, leading to sluggish bowel movements, bloating, and constipation. By enhancing cholinergic stimulation, pyridostigmine can increase intestinal peristalsis and restore bowel function. This may be particularly relevant in post-operative settings where intestinal motility is temporarily impaired.
Pyridostigmine bromide is available internationally under various brand names, most notably Mestinon, which is one of the most widely recognised formulations globally. The Orifarm formulation is a generic equivalent manufactured by Orifarm Healthcare A/S. The World Health Organization (WHO) includes pyridostigmine on its Model List of Essential Medicines, underscoring its importance in global healthcare.
What Should You Know Before Taking Pyridostigmin Orifarm?
Contraindications
You must not take Pyridostigmin Orifarm if you are allergic to pyridostigmine bromide or any of the other ingredients in the medication. You must also not use it if you have a mechanical intestinal obstruction (physical blockage in the gut) or a urinary tract obstruction. These are absolute contraindications because pyridostigmine increases smooth muscle contraction — using it when a physical blockage is present could lead to dangerous complications including bowel perforation or bladder rupture.
In clinical practice, it is essential that these conditions are ruled out before initiating pyridostigmine therapy. If you develop symptoms of intestinal or urinary obstruction while taking the medication (such as severe abdominal pain, vomiting, inability to pass stool or urine), you should stop taking the medicine and contact your doctor or emergency services immediately.
Warnings and Precautions
Speak with your doctor, pharmacist, or nurse before taking Pyridostigmin Orifarm if you have any of the following conditions:
- Respiratory conditions — asthma or chronic obstructive pulmonary disease (COPD). Pyridostigmine can increase bronchial secretions and cause bronchospasm, which may worsen these conditions.
- Cardiac conditions — irregular or slow heart rate (arrhythmias, bradycardia), low blood pressure (hypotension), or recent coronary artery occlusion. The cholinergic effects of pyridostigmine can further slow heart rate and lower blood pressure.
- Vagotomy — if you have had surgical interruption of the vagus nerve, the response to pyridostigmine may be altered.
- Peptic ulcer disease — pyridostigmine stimulates gastric acid secretion, which may exacerbate existing ulcers.
- Epilepsy or parkinsonism — cholinergic stimulation may affect seizure threshold or worsen parkinsonian symptoms.
- Hyperthyroidism (thyrotoxicosis) — patients with overactive thyroid may have increased sensitivity to the cardiac effects of cholinergic agents.
- Renal impairment — pyridostigmine is primarily excreted by the kidneys, so reduced kidney function may lead to drug accumulation and increased risk of side effects. Dose adjustment may be necessary.
- Previous thymectomy — if you have had your thymus gland removed, your doctor should be informed as this may influence the management of myasthenia gravis and dosing requirements.
Excessive doses of pyridostigmine can precipitate a cholinergic crisis, a potentially life-threatening condition characterised by severe muscle weakness (paradoxically similar to myasthenic crisis), excessive secretions, breathing difficulties, and bradycardia. If you experience worsening muscle weakness despite taking your medication, do not increase the dose on your own — seek immediate medical attention. Only your physician can distinguish between myasthenic crisis (underdosing) and cholinergic crisis (overdosing).
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using this medicine.
Pregnancy: Data from the use of pyridostigmine in pregnant women are limited. Animal studies have shown effects on the foetus. Pyridostigmin Orifarm should only be used during pregnancy when the potential benefit justifies the potential risk to the foetus. There have been rare reports of transient neonatal muscle weakness (neonatal myasthenia) in infants born to mothers taking anticholinesterase agents, which typically resolves within a few weeks. The International Myasthenia Gravis Guidelines suggest that pyridostigmine can be continued during pregnancy when necessary, but careful monitoring is advised.
Breastfeeding: Pyridostigmine passes into breast milk, although in small quantities. The benefits of treatment for the mother and the benefits of breastfeeding must be weighed against the potential risks to the infant. Your doctor will help you make this decision based on your individual situation.
Fertility: Studies have not demonstrated any negative effects on the ability to conceive.
Driving and Operating Machinery
Pyridostigmin Orifarm may cause side effects such as low blood pressure and visual disturbances (including difficulty focusing and constricted pupils) that could impair your ability to drive or operate machinery. You should be aware of how this medication affects you before engaging in activities that require alertness and sharp vision. If you experience dizziness, blurred vision, or other symptoms that affect your concentration, do not drive or operate heavy machinery until these effects have resolved.
Pyridostigmin Orifarm sugar-coated tablets contain lactose monohydrate and sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This is particularly relevant for patients with rare hereditary conditions such as galactose intolerance, total lactase deficiency, glucose-galactose malabsorption, fructose intolerance, or sucrase-isomaltase insufficiency.
How Does Pyridostigmin Orifarm Interact with Other Drugs?
The therapeutic effect of Pyridostigmin Orifarm can be significantly affected when taken concurrently with certain other medications. It is critically important to tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter products and herbal supplements.
Drug interactions with pyridostigmine are clinically significant because the neuromuscular junction is a delicate system. Medications that either enhance or reduce cholinergic transmission can profoundly affect muscle strength in patients with myasthenia gravis. Some interactions may worsen myasthenic symptoms, while others may increase the risk of cholinergic side effects.
Major Interactions
| Drug / Drug Class | Effect on Treatment | Clinical Significance |
|---|---|---|
| Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) | May worsen neuromuscular blockade and reduce pyridostigmine effectiveness | High — can precipitate myasthenic crisis |
| Neuromuscular blocking agents (succinylcholine, rocuronium) | Unpredictable potentiation or antagonism of neuromuscular blockade | High — requires anaesthesia specialist monitoring |
| Immunosuppressants (azathioprine, ciclosporin, mycophenolate) | May alter the underlying myasthenia gravis disease activity, changing pyridostigmine requirements | Moderate — dose adjustment often needed |
| Corticosteroids (prednisolone, methylprednisolone) | Initial worsening of myasthenia possible; long-term improvement may reduce pyridostigmine need | Moderate — requires careful dose titration |
| Antiarrhythmic drugs (quinidine, procainamide) | May antagonise the cholinergic effect of pyridostigmine; can also worsen myasthenia | Moderate — may need alternative antiarrhythmics |
| Local and general anaesthetics | Can impair neuromuscular transmission; altered sensitivity to muscle relaxants | High — inform anaesthetist of pyridostigmine use |
Minor Interactions
| Drug / Drug Class | Effect on Treatment | Clinical Significance |
|---|---|---|
| Atropine and hyoscine (anticholinergics) | Oppose the cholinergic effects of pyridostigmine; may be used deliberately to manage muscarinic side effects | Low — sometimes used therapeutically alongside pyridostigmine |
| Beta-blockers (propranolol, atenolol) | Additive bradycardic effect when combined with pyridostigmine | Low to Moderate — monitor heart rate |
| Methylcellulose-containing products | May reduce absorption of pyridostigmine from the gastrointestinal tract | Low — consider timing of doses |
It is particularly important that if you require surgery or anaesthesia, you inform the anaesthetist that you are taking Pyridostigmin Orifarm. The interaction between cholinesterase inhibitors and neuromuscular blocking agents used during surgery requires careful planning and monitoring. International guidelines from the European Medicines Agency (EMA) and the British National Formulary (BNF) recommend close perioperative collaboration between neurologists and anaesthetists for patients with myasthenia gravis.
What Is the Correct Dosage of Pyridostigmin Orifarm?
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The dose is determined by your physician and tailored individually to your needs. Never change the prescribed dose without consulting your doctor.
Dosage titration in myasthenia gravis is particularly important because the optimal dose varies considerably between individuals and can change over time as the disease fluctuates. The goal is to find the minimum effective dose that provides adequate symptom control without causing excessive cholinergic side effects. Your doctor will typically start with a lower dose and increase gradually until the best balance between efficacy and tolerability is achieved.
Adults
Myasthenia Gravis
Recommended dose: 60–180 mg taken 3–6 times per day
Total daily dose: Typically 180–720 mg, individualised
Duration of effect: 3–6 hours per dose
The dose is usually distributed throughout waking hours, timed to coincide with peak activity demands. Many patients find it helpful to take a dose 30–45 minutes before meals to assist with chewing and swallowing. The dosing interval is typically adjusted based on when symptoms return.
Intestinal Atony
Recommended dose: 60 mg at appropriate intervals (e.g., every 4 hours)
The dose and frequency are adjusted based on clinical response and bowel function.
Children
The use of pyridostigmine in children with myasthenia gravis may be appropriate but requires specialist paediatric neurological supervision. Dosing in children is typically calculated based on body weight and adjusted according to individual response. According to the BNF for Children and international paediatric neurology guidelines, starting doses are usually lower than adult doses and carefully titrated upward. Your child's neurologist will determine the appropriate regimen.
Elderly
Elderly patients may be more sensitive to the effects of pyridostigmine, particularly the cardiovascular and gastrointestinal side effects. Reduced kidney function, which is common in older adults, may result in slower drug clearance and increased risk of accumulation. Dose initiation at the lower end of the recommended range and careful upward titration is generally recommended. The European Medicines Agency (EMA) recommends regular monitoring of renal function in elderly patients taking pyridostigmine long-term.
Missed Dose
If you forget to take a dose of Pyridostigmin Orifarm, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten tablet. Doubling the dose could lead to excessive cholinergic stimulation and potentially serious side effects.
If you frequently forget doses, consider setting alarms or using a pill organiser. Consistent dosing is important for maintaining stable symptom control in myasthenia gravis.
Overdose
If you or someone else has taken too much Pyridostigmin Orifarm, or if a child has accidentally swallowed the medicine, contact your doctor, hospital emergency department, or poison control centre immediately.
An overdose of pyridostigmine can cause a cholinergic crisis, which is a medical emergency. Symptoms of overdose include:
- Respiratory: breathing difficulties, increased bronchial secretions, bronchospasm
- Gastrointestinal: abdominal cramps, nausea, vomiting, diarrhoea, increased salivation
- Cardiovascular: low blood pressure (hypotension), slow heart rate (bradycardia), cardiac arrest
- Muscular: muscle twitching (fasciculations), muscle weakness, paralysis, generalised weakness
- Ocular: constricted pupils (miosis), excessive tearing
- Neurological: agitation, confusion, speech difficulties, nervousness, visual hallucinations, seizures, and in severe cases, coma
- Other: excessive sweating
Treatment of cholinergic crisis typically involves discontinuation of pyridostigmine and administration of atropine (an anticholinergic agent) to counteract the excessive muscarinic effects. Respiratory support, including mechanical ventilation, may be necessary. The antidote and treatment should be administered under medical supervision in a hospital setting.
What Are the Side Effects of Pyridostigmin Orifarm?
The side effects of pyridostigmine are predominantly cholinergic in nature — they arise from the same mechanism by which the drug exerts its therapeutic effect. Because pyridostigmine inhibits acetylcholinesterase non-selectively, it enhances cholinergic activity not only at the neuromuscular junction (the desired effect) but also at muscarinic receptors in the gastrointestinal tract, cardiovascular system, glands, and eyes. The balance between therapeutic benefit and side effects is managed through careful dose titration.
Side effects are generally dose-dependent: they become more pronounced at higher doses and tend to diminish when the dose is reduced. If you experience troublesome side effects, your doctor may adjust your dosing schedule or prescribe a small dose of an anticholinergic agent (such as atropine or hyoscine) to counteract the muscarinic effects while preserving the beneficial nicotinic (neuromuscular) effects.
Common
- Constricted pupils (miosis), increased tear production, accommodation difficulties (difficulty focusing and reading fine print), eye inflammation
- Irregular heart rhythm, increased mucus production in airways (particularly in patients with existing lung disease), breathing difficulties, runny nose
- Nausea, vomiting, diarrhoea, increased intestinal movements, abdominal discomfort and cramps
- Increased saliva and sweat production
- Muscle weakness, small muscle twitching (fasciculations), tremor, cramps
- Difficulty urinating, loss of appetite
Uncommon
- Dizziness
- Restlessness
- Difficulty falling asleep (insomnia)
Rare
- Skin rash
- Hair loss (alopecia)
Very Rare
- Heart rhythm disturbances (arrhythmias)
- Urticaria (hives)
Frequency Not Known
- Prinzmetal angina (variant angina with coronary artery spasms)
- Flushing (skin redness)
- Low blood pressure (hypotension)
- Fainting (syncope)
- Drug hypersensitivity reactions
If you experience any side effects, including any not listed above, talk to your doctor, pharmacist, or nurse. Reporting suspected adverse reactions after the medicine has been authorised is important, as it allows continuous monitoring of the medicine's benefit-risk balance. In the UK, adverse reactions can be reported via the Yellow Card Scheme. In the EU, reports can be submitted through national pharmacovigilance systems.
Many common side effects of pyridostigmine can be managed effectively. Taking the medication with food may reduce gastrointestinal symptoms. If excessive salivation or sweating is problematic, your doctor may prescribe a low dose of an anticholinergic such as propantheline or glycopyrronium to manage these muscarinic effects. Always discuss any side effects with your healthcare team before making dose changes.
How Should You Store Pyridostigmin Orifarm?
Proper storage of medications is essential to ensure their effectiveness and safety throughout their shelf life. Pyridostigmin Orifarm should be stored according to the following guidelines:
- Temperature: Store at a maximum temperature of 25°C (77°F). Do not store in the refrigerator or freezer.
- Children: Keep out of the sight and reach of children at all times. Consider using a locked medicine cabinet.
- Expiry date: Do not use after the expiry date stated on the packaging after “EXP”. The expiry date refers to the last day of the stated month.
- Disposal: Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
If you travel with your medication, ensure it is kept at the appropriate temperature and avoid exposing it to extreme heat or humidity. When flying, carry your medicines in your hand luggage with the original packaging and a copy of your prescription, particularly when travelling internationally.
What Does Pyridostigmin Orifarm Contain?
Active substance: Each sugar-coated tablet contains 60 mg pyridostigmine bromide.
Tablet core excipients: Colloidal anhydrous silica (E551), povidone, lactose monohydrate, talc (E553b), magnesium stearate (E470b), pregelatinised starch.
Sugar coating excipients: Sucrose, talc (E553b), hypromellose (E464), macrogol/PEG, medium-chain triglycerides, glycerol monostearate (E471), polyvinyl alcohol, titanium dioxide (E171), yellow and red iron oxide (E172).
Appearance and Pack Sizes
Pyridostigmin Orifarm is a reddish-brown, biconvex, round, sugar-coated tablet with a diameter of 10 mm.
Pack sizes:
- Blister packs: 20, 100, 150, 160, or 180 tablets
- Plastic bottle with child-resistant cap: 150 tablets
Not all pack sizes may be marketed in all countries. The marketing authorisation holder is Orifarm Healthcare A/S, Energivej 15, 5260 Odense S, Denmark.
Frequently Asked Questions
Both conditions cause severe muscle weakness, but they have opposite causes and require opposite treatments. A myasthenic crisis occurs when myasthenia gravis symptoms worsen significantly, often due to infection, stress, or inadequate medication — the body needs more acetylcholine activity. A cholinergic crisis occurs when there is too much acetylcholine due to excessive pyridostigmine dosage. In a cholinergic crisis, you may also experience pronounced muscarinic symptoms such as excessive salivation, sweating, diarrhoea, and constricted pupils. Distinguishing between the two is critical because treatment for a myasthenic crisis involves increasing medication, while treatment for a cholinergic crisis involves stopping or reducing the medication and administering atropine. This distinction should always be made by a physician, typically in a hospital setting.
Yes, pyridostigmine can be taken with or without food. In fact, taking it with food or a snack may help reduce common gastrointestinal side effects such as nausea, abdominal cramps, and diarrhoea. Many patients with myasthenia gravis find it helpful to take their dose approximately 30–45 minutes before mealtimes, as this allows the medication to take effect in time to help with chewing and swallowing. The tablets should always be swallowed with plenty of water.
Pyridostigmine typically begins to work within 30 to 45 minutes after taking a tablet by mouth. The peak effect usually occurs 1 to 2 hours after dosing. The duration of action is approximately 3 to 6 hours, depending on the dose taken. Because of this relatively short duration, most patients need to take multiple doses throughout the day. Your doctor will help you establish a dosing schedule that provides the best symptom coverage during your waking hours.
No, pyridostigmine is a symptomatic treatment — it improves muscle strength and reduces fatigue, but it does not address the underlying autoimmune process that causes myasthenia gravis. To modify the disease course, doctors often prescribe additional immunosuppressive or immunomodulatory therapies such as corticosteroids, azathioprine, mycophenolate mofetil, or rituximab. Some patients may also benefit from thymectomy (surgical removal of the thymus gland). Pyridostigmine remains an essential component of treatment because it provides rapid and noticeable symptomatic relief while other therapies take weeks or months to reach full effect.
If you are scheduled for any surgical procedure, it is essential that you inform your anaesthetist that you are taking pyridostigmine. This is because the drug interacts with neuromuscular blocking agents commonly used during surgery. Patients taking pyridostigmine may have increased sensitivity to depolarising muscle relaxants (such as succinylcholine) and relative resistance to non-depolarising agents (such as rocuronium). Additionally, your myasthenia gravis diagnosis itself affects anaesthetic management. International guidelines recommend that surgery in myasthenia gravis patients be performed at centres with experience in managing the condition, with an intensive care unit available for post-operative monitoring.
There is no specific contraindication to moderate alcohol consumption while taking pyridostigmine. However, alcohol can exacerbate some side effects such as dizziness, blurred vision, and gastrointestinal upset. Additionally, alcohol can independently worsen muscle weakness and fatigue in patients with myasthenia gravis. It is generally advisable to limit alcohol intake and to discuss your individual situation with your doctor. If you notice that alcohol worsens your symptoms, you should avoid it.
References and Medical Sources
This article is based on peer-reviewed medical literature, international guidelines, and regulatory documents. All information has been verified against the following sources:
- Sanders DB, Wolfe GI, Benatar M, et al. “International consensus guidance for management of myasthenia gravis: Executive summary.” Neurology. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790
- Gilhus NE, Tzartos S, Evoli A, et al. “Myasthenia gravis.” Nature Reviews Disease Primers. 2019;5(1):30. doi:10.1038/s41572-019-0079-y
- European Medicines Agency (EMA). Summary of Product Characteristics for pyridostigmine bromide. Accessed January 2026.
- British National Formulary (BNF). Pyridostigmine bromide monograph. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List. 2023.
- Narayanaswami P, Sanders DB, Wolfe G, et al. “International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.” Neurology. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124
- Sussman J, Farrugia ME, Maddison P, et al. “Myasthenia gravis: Association of British Neurologists’ management guidelines.” Practical Neurology. 2015;15(3):199-206. doi:10.1136/practneurol-2015-001126
- Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. “Treatment of Myasthenia Gravis.” Neurologic Clinics. 2018;36(2):311-337. doi:10.1016/j.ncl.2018.01.011
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with expertise in neurology, neuromuscular medicine, and clinical pharmacology.
Prepared by licensed physicians with clinical experience in neurology and pharmacology, following evidence-based medicine principles and the GRADE framework for assessing evidence quality.
Independently reviewed by the iMedic Medical Review Board according to international guidelines from the AAN, EAN, EMA, and WHO. All medical claims are verified against peer-reviewed literature.
iMedic has no commercial funding, pharmaceutical sponsorship, or advertising. All content is produced independently to ensure objectivity and accuracy. Our editorial process follows the principles outlined in our editorial standards.